The hair-loss treatment market is expanding rapidly, and drugmakers are stepping up efforts to develop new medicines that address the limits of existing therapies. With options narrowed by the burden of long-term daily use, side-effect concerns and restrictions by sex, demand is rising for safer, more sustainable treatments.
According to global research firm Research Nester, the hair-loss drug market is projected to grow from $11.44 billion in 2025 to $33.07 billion in 2035. Population aging and greater interest in appearance are cited as key drivers.
Even so, treatment choices in clinics remain limited. The most widely used therapies are oral finasteride and dutasteride and topical minoxidil. Finasteride and dutasteride work by suppressing DHT, a male hormone linked to hair loss, but their use is restricted for women of childbearing age. Patients also face the burden of taking the drugs daily.
To overcome those constraints, companies are pursuing drugs that target new pathways beyond hormone suppression, as well as long-acting formulations designed to sharply reduce dosing frequency. JW Pharmaceutical is developing JW0061, a first-in-class candidate involved in the proliferation of hair follicle cells. Because it does not directly suppress hormones, it could also be used for women.
Development of injectable treatments aimed at improving convenience is also accelerating. Chong Kun Dang is developing CKD-843, an improved drug that converts oral dutasteride into an intramuscular injection given once every three months. Daewoong Pharmaceutical and Inventage Lab are jointly developing IVL3001, a long-acting injectable based on oral finasteride, designed for monthly dosing with effects lasting up to three months.
Expectations have also risen after discussions resurfaced on reviewing national health insurance coverage for hair-loss drugs, following an instruction by President Lee Jae-myung. Still, analysts say the market outlook should distinguish between conditions: receding-hairline and crown hair loss are hormone-related cosmetic conditions, while alopecia areata stems from immune-system abnormalities and requires a different approach.
Alopecia areata patients worldwide are estimated at about 147 million. With more young patients, surveys show 40% of men experience some level of hair loss by age 35. In South Korea, Eli Lilly’s Olumiant (baricitinib) is approved, but patients face heavy costs because it is not covered under the special reimbursement program.
Kim Hyun-jung, a dermatology professor at Gachon University Gil Medical Center, said severe alopecia areata is a condition in which immune cells attack hair follicles, making Janus kinase, or JAK, inhibitors essential. She added that studies have also reported benefits from a JAK inhibitor with a different mechanism, upadacitinib, in patients who did not respond to existing treatments. “It should not stop at a single drug,” she said, calling for the entry of more follow-on medicines alongside reimbursement discussions."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.